A series ofN-（furan-2-ylmethyl）-lH-indole-3-carboxamide derivatives（6a--6p） was designed and synthe- sized for developing novel indole scaffolds as anticancer agents targeting the epidemal growth factor receptor ...A series ofN-（furan-2-ylmethyl）-lH-indole-3-carboxamide derivatives（6a--6p） was designed and synthe- sized for developing novel indole scaffolds as anticancer agents targeting the epidemal growth factor receptor （EGFR）, and the cytotoxic activities of the target compounds were evaluated against three EGFR high-expressed cancer cell lines[human lung adenocarcinoma cell line（A549）, Henrietta Lacks strain of cancer cell line（HeLa） and human colorectal cancer cell line（SW480）], one EGFR low-expressed cell line（human liver cancer cell line, HepG2） and one human liver normal cell line（HL7702） using 3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyl tetrazolium bromide （MTT） assay, Some target compounds exhibited potent anficancer activities against A549, HeLa, SW480 and weak activities on HepG2, which signifies that the target compounds are likely to be EGFR inhibitors as expected. And they showed weak cytotoxic effects on HL7702, which implies the target compounds are probably to be of low toxicity against normal cells. Among them, the target compound 1-ethyl-N-（fttran-2-ylmethyl）-5-{2-{ [2-（2-methoxy- phenoxy）ethyl]amino}-2-oxoethoxy}-2-methyl-1H-indole-3-carboxamide（6p） with 2-{[2-（2-methoxyphenoxy）ethyl]- amino}-2-oxoethoxy group at the C5 position of the N-（furan-2-ylmethyl）-lH-indole-3-carboxamide scaffold exhibited the most potent anticancer activity. Also the binding interaction of the target compound 6p with EGFR was explored by molecular docking. Conclusively, the novel indole scaffold may be beneficial to investigate new anticancer agents for targeting the EGFR.展开更多
The relationship between antiproliferative effect of human IFN γ EGF 3 fusion protein and the influence of EGF receptor binding activity has been studied on A431 cell line. Antiproliferative activity of human IF...The relationship between antiproliferative effect of human IFN γ EGF 3 fusion protein and the influence of EGF receptor binding activity has been studied on A431 cell line. Antiproliferative activity of human IFN γ EGF 3 was higher than that of its parent IFN γ. In the 125 I EGF receptor competition experiment, the inhibition of EGF receptor binding capacity on the target cells was observed in the treatments of human IFN γ or IFN γ EGF 3, but the later was more significant. Our data suggests that the antiproliferative effects by IFN γ and its fusion protein are closely related to their EGF receptor competitions.展开更多
目的:探讨槐定碱对神经胶质瘤U87细胞增殖和侵袭的抑制作用以及U87细胞DNA拓扑异构酶I(DNA TOP I)、EGFR-酪氨酸激酶(EGFR-TK)、基质金属蛋白酶2(MMP2)和氨肽酶N(APN)活性的影响。方法:将不同浓度槐定碱加入到神经胶质瘤U87细胞株中,利...目的:探讨槐定碱对神经胶质瘤U87细胞增殖和侵袭的抑制作用以及U87细胞DNA拓扑异构酶I(DNA TOP I)、EGFR-酪氨酸激酶(EGFR-TK)、基质金属蛋白酶2(MMP2)和氨肽酶N(APN)活性的影响。方法:将不同浓度槐定碱加入到神经胶质瘤U87细胞株中,利用MTT法测定槐定碱对U87细胞和人脑正常星型胶质HEB细胞生长的抑制作用,酶标仪法检测槐定碱对细胞凋亡蛋白caspase-3活性,采用Transwell小室法分析U87细胞的侵袭能力;采用非放射性NF-κB EMSA试剂盒测定U87细胞中NF-κB表达。结果:随着槐定碱浓度的增加(5、10、25、50、100μmol/L),神经胶质瘤U87细胞生长抑制率不断的增加,但HEB细胞的生长并未受到明显的抑制[(11.23±1.18)%vs(2.43±0.29)%、(22.48±3.21)%vs(3.65±0.42)%、(43.21±4.09)%vs(4.03±0.55)%、(57.31±5.09)%vs(5.21±0.43)%、(77.98±6.98)%vs(7.22±0.78)%,均P<0.05];与空白组比较,槐定碱存在下的U87细胞侵袭能力明显降低[(87.43±7.33)%、(65.12±6.16)%、(50.63±4.56)%、(35.32±4.04)%、(23.46±2.32)%vs(120.32±9.32),均P<0.05]。槐定碱对DNA TOP I、EGFR-TK、APN和MMP-2的半抑制率IC_(50)分别为(22.43±2.21)、(31.25±3.09)、(6.32±0.32)和(8.23±0.63)μmol/L,但U87细胞中凋亡蛋白caspase-3活性呈增强趋势;槐定碱能够下调NF-κB信号的表达。结论:低毒性的槐定碱可能通过降低DNA TOP I、EGFR-TK、APN和MMP-2活性,并下调NF-κB信号通路和激活凋亡caspase-3酶联反应的方式,对神经胶质瘤U87细胞的侵袭、增殖和信号通路产生抑制作用。展开更多
目的:探讨肺腺癌新分类与表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变之间的关系。方法:共纳入中日友好医院2010年3月至2014年12月经手术肺切除术后且病理证实为浸润性肺腺癌患者94例,对其进行EGFR基因突变检测;...目的:探讨肺腺癌新分类与表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变之间的关系。方法:共纳入中日友好医院2010年3月至2014年12月经手术肺切除术后且病理证实为浸润性肺腺癌患者94例,对其进行EGFR基因突变检测;入组患者均按照2011年国际肺癌研究学会(Intemational Association for the Study of Lung Cancer,IASLC)、美国胸科学会(American Thoracic Society,ATS)和欧洲呼吸学会(European Respiratory Society,ERS)分类方法进行肺腺癌亚型分类,分析肺腺癌新分类与EGFR基因突变之间的关系;采用SPSS 20.0统计软件卡方检验分析,P<0.05为差异有统计学意义。结果:入组的94例肺腺癌患者,男、女患者均为47例;年龄24~79岁,中位年龄61岁,60岁及以上48例,60岁以下46例;既往或现在吸烟者34例,不吸烟者60例。根据病理分期,Ⅰ期患者34例,Ⅱ期患者17例,Ⅲ期24例,Ⅳ期19例。EGFR基因外显子19突变例数22,外显子20突变例数2,外显子21突变例数26,外显子10和21同时突变例数1,入组患者EGFR基因总突变率为54.3%(51/94),其中腺泡状为主型肺腺癌EGFR突变例数24例,伏壁状为主型肺腺癌14例,乳头状为主型肺腺癌与实体状为主型肺腺癌均为5例,微乳头状为主型肺腺癌3例,黏液腺癌为0;腺泡状为主型肺腺癌较非腺泡状为主型肺腺癌EGFR突变率高,但差异无统计学意义(66.7%vs.46.6%,P=0.057);实体状为主型肺腺癌较非实体状为主型肺腺癌EGFR突变率低,差异有统计学意义(26.3%vs.61.3%,P=0.005);黏液腺癌较非黏液腺癌EGFR基因突变率低,差异有统计学意义(0 vs.57.3%,P=0.018)。结论:不同的病理亚型肺腺癌EGFR突变率存在差异,其中腺泡状为主型肺腺癌较非腺泡状为主型肺腺癌的EGFR基因突变发生率高,实性为主型肺腺癌较非实性为主肺腺癌EGFR突变发生率低,黏液腺癌较非黏液腺癌EGFR基因突变率低。展开更多
基金Supported by the National Natural Science Foundation of China（No.21342006） and the Program for the Innovative Research Team of the Ministry of Education of China（No.IRT_14R36）.
文摘A series ofN-（furan-2-ylmethyl）-lH-indole-3-carboxamide derivatives（6a--6p） was designed and synthe- sized for developing novel indole scaffolds as anticancer agents targeting the epidemal growth factor receptor （EGFR）, and the cytotoxic activities of the target compounds were evaluated against three EGFR high-expressed cancer cell lines[human lung adenocarcinoma cell line（A549）, Henrietta Lacks strain of cancer cell line（HeLa） and human colorectal cancer cell line（SW480）], one EGFR low-expressed cell line（human liver cancer cell line, HepG2） and one human liver normal cell line（HL7702） using 3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyl tetrazolium bromide （MTT） assay, Some target compounds exhibited potent anficancer activities against A549, HeLa, SW480 and weak activities on HepG2, which signifies that the target compounds are likely to be EGFR inhibitors as expected. And they showed weak cytotoxic effects on HL7702, which implies the target compounds are probably to be of low toxicity against normal cells. Among them, the target compound 1-ethyl-N-（fttran-2-ylmethyl）-5-{2-{ [2-（2-methoxy- phenoxy）ethyl]amino}-2-oxoethoxy}-2-methyl-1H-indole-3-carboxamide（6p） with 2-{[2-（2-methoxyphenoxy）ethyl]- amino}-2-oxoethoxy group at the C5 position of the N-（furan-2-ylmethyl）-lH-indole-3-carboxamide scaffold exhibited the most potent anticancer activity. Also the binding interaction of the target compound 6p with EGFR was explored by molecular docking. Conclusively, the novel indole scaffold may be beneficial to investigate new anticancer agents for targeting the EGFR.
文摘The relationship between antiproliferative effect of human IFN γ EGF 3 fusion protein and the influence of EGF receptor binding activity has been studied on A431 cell line. Antiproliferative activity of human IFN γ EGF 3 was higher than that of its parent IFN γ. In the 125 I EGF receptor competition experiment, the inhibition of EGF receptor binding capacity on the target cells was observed in the treatments of human IFN γ or IFN γ EGF 3, but the later was more significant. Our data suggests that the antiproliferative effects by IFN γ and its fusion protein are closely related to their EGF receptor competitions.
文摘目的:探讨槐定碱对神经胶质瘤U87细胞增殖和侵袭的抑制作用以及U87细胞DNA拓扑异构酶I(DNA TOP I)、EGFR-酪氨酸激酶(EGFR-TK)、基质金属蛋白酶2(MMP2)和氨肽酶N(APN)活性的影响。方法:将不同浓度槐定碱加入到神经胶质瘤U87细胞株中,利用MTT法测定槐定碱对U87细胞和人脑正常星型胶质HEB细胞生长的抑制作用,酶标仪法检测槐定碱对细胞凋亡蛋白caspase-3活性,采用Transwell小室法分析U87细胞的侵袭能力;采用非放射性NF-κB EMSA试剂盒测定U87细胞中NF-κB表达。结果:随着槐定碱浓度的增加(5、10、25、50、100μmol/L),神经胶质瘤U87细胞生长抑制率不断的增加,但HEB细胞的生长并未受到明显的抑制[(11.23±1.18)%vs(2.43±0.29)%、(22.48±3.21)%vs(3.65±0.42)%、(43.21±4.09)%vs(4.03±0.55)%、(57.31±5.09)%vs(5.21±0.43)%、(77.98±6.98)%vs(7.22±0.78)%,均P<0.05];与空白组比较,槐定碱存在下的U87细胞侵袭能力明显降低[(87.43±7.33)%、(65.12±6.16)%、(50.63±4.56)%、(35.32±4.04)%、(23.46±2.32)%vs(120.32±9.32),均P<0.05]。槐定碱对DNA TOP I、EGFR-TK、APN和MMP-2的半抑制率IC_(50)分别为(22.43±2.21)、(31.25±3.09)、(6.32±0.32)和(8.23±0.63)μmol/L,但U87细胞中凋亡蛋白caspase-3活性呈增强趋势;槐定碱能够下调NF-κB信号的表达。结论:低毒性的槐定碱可能通过降低DNA TOP I、EGFR-TK、APN和MMP-2活性,并下调NF-κB信号通路和激活凋亡caspase-3酶联反应的方式,对神经胶质瘤U87细胞的侵袭、增殖和信号通路产生抑制作用。
文摘目的:探讨肺腺癌新分类与表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变之间的关系。方法:共纳入中日友好医院2010年3月至2014年12月经手术肺切除术后且病理证实为浸润性肺腺癌患者94例,对其进行EGFR基因突变检测;入组患者均按照2011年国际肺癌研究学会(Intemational Association for the Study of Lung Cancer,IASLC)、美国胸科学会(American Thoracic Society,ATS)和欧洲呼吸学会(European Respiratory Society,ERS)分类方法进行肺腺癌亚型分类,分析肺腺癌新分类与EGFR基因突变之间的关系;采用SPSS 20.0统计软件卡方检验分析,P<0.05为差异有统计学意义。结果:入组的94例肺腺癌患者,男、女患者均为47例;年龄24~79岁,中位年龄61岁,60岁及以上48例,60岁以下46例;既往或现在吸烟者34例,不吸烟者60例。根据病理分期,Ⅰ期患者34例,Ⅱ期患者17例,Ⅲ期24例,Ⅳ期19例。EGFR基因外显子19突变例数22,外显子20突变例数2,外显子21突变例数26,外显子10和21同时突变例数1,入组患者EGFR基因总突变率为54.3%(51/94),其中腺泡状为主型肺腺癌EGFR突变例数24例,伏壁状为主型肺腺癌14例,乳头状为主型肺腺癌与实体状为主型肺腺癌均为5例,微乳头状为主型肺腺癌3例,黏液腺癌为0;腺泡状为主型肺腺癌较非腺泡状为主型肺腺癌EGFR突变率高,但差异无统计学意义(66.7%vs.46.6%,P=0.057);实体状为主型肺腺癌较非实体状为主型肺腺癌EGFR突变率低,差异有统计学意义(26.3%vs.61.3%,P=0.005);黏液腺癌较非黏液腺癌EGFR基因突变率低,差异有统计学意义(0 vs.57.3%,P=0.018)。结论:不同的病理亚型肺腺癌EGFR突变率存在差异,其中腺泡状为主型肺腺癌较非腺泡状为主型肺腺癌的EGFR基因突变发生率高,实性为主型肺腺癌较非实性为主肺腺癌EGFR突变发生率低,黏液腺癌较非黏液腺癌EGFR基因突变率低。
